Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1293-1300

  Ayanian, John Z ^a   Zaslavsky, Alan M ^a   Fuchs, Charles S ^a   Guadagnoli, Edward ^a   Creech, Cynthia M ^a   Cress, Rosemary D ^a   O'Connor, Lilia C ^a   West, Dee W ^a   Allen, Mark E ^a   Wolf, Robert E ^a   Wright, William E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PHYSICIAN; POPULATION BIOLOGY; PRIORITY JOURNAL; TREATMENT INDICATION; ADOLESCENT; AGE; COHORT ANALYSIS; COLORECTAL TUMOR; FEMALE; HOSPITAL; MALE; MARRIAGE; MIDDLE AGED; PATHOLOGY; PATIENT ATTITUDE; REGISTER; UNITED STATES; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CALIFORNIA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; HOSPITALS; HUMANS; MALE; MARITAL STATUS; MIDDLE AGED; NEOPLASM STAGING; PATIENT ACCEPTANCE OF HEALTH CARE; RADIOTHERAPY, ADJUVANT; REGISTRIES;

EID: 0038175326     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.178     Document Type: Article

References (55)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil-The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447-1456, 1989
3. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
4. Francini G, Petrioli R, Lorenzini L, et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106:899-906, 1994
5. IMPACT Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysts of Colon Cancer Trials (IMPACT) Investigators. Lancet 345:939-944, 1995
6. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
7. The Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 10:549-557, 1992
8. Douglass HO Jr, Moertel CG, Mayer RJ, et al: Survival after postoperative combination treatment of rectal cancer. N Engl J Med 315:1294-1295, 1986
9. Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
10. National Institutes of Health: NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. J Am Med Assoc 264:1444-1450, 1990
11. Hodgson DC, Fuchs CS, Ayanian JZ: Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93:501-515, 2001
12. Jessup JM, McGinnis LS, Steele GD Jr, et al: The National Cancer Data Base report on colon cancer. Cancer 78:918-926, 1996
13. Jessup JM, Stewart AK, Menck HR: The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-1995. Cancer 83:2408-2418, 1998
14. Bickell NA, Chassin MR: Determining the quality of breast cancer care: Do tumor registries measure up? Ann Intern Med 132:705-710, 2000
15. Schrag D, Cramer LD, Bach PB, et al: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93:850-857, 2001
16. Schrag D, Gelfand SE, Bach PB, et al: Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results-Medicare. J Clin Oncol 19:3712-3718, 2001
17. Goodwin JS, Hunt WC, Samet JM: Determinants of cancer therapy in elderly patients. Cancer 72:594-601, 1993
18. Newcomb PA, Carbone PP: Cancer treatment and age: Patient perspectives. J Natl Cancer Inst 85:1580-1584, 1993
19. Mahoney T, Kuo Y-H, Topilow A, et al: Stage III colon cancers. Why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 135: 182-185, 2000
20. Hewitt M, Simone JV (eds): Ensuring Quality Cancer Care. Washington, DC, National Academy Press, 1999
21. Hewitt M, Simone JV (eds) Enhancing Data Systems to Improve the Quality of Cancer Care. Washington, DC, National Academy Press, 2000
22. Morris CR, Cohen R, Perkins CI, et al: Cancer in California: 1988-1996. Sacramento, CA, Department of Health Services, Cancer Surveillance Section, 1999
23. Tucker TC, Howe HI, Weir HK: Certification for population-based cancer registries. J Reg Mgmt 26:24-27, 1999
24. Fleming ID, Cooper JS, Henson DE, et al (eds): American Joint Committee on Cancer: Manual for Staging of Cancer (ed 5). Philadelphia, PA, Lippincott-Raven, 1997
25. Krieger N: Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. Am J Public Health 82:703-710, 1992
26. Chiu CW, Yucel RM, Zanutto E, et al: Using matched substitutes to improve imputations for geographically linked databases. Proc Joint Stat Mtgs, 2001
27. Rubin DB, Zanutto E: Using matched substitutes to adjust for nonignorable nonresponse through multiple imputations, in: Groves RM, Dillman DA, Eltinge JL, et al (eds): Survey Nonresponse. New York, NY, Wiley, 2002, pp 389-402
28. Commission on Cancer: Cancer Programs Approved. Chicago, IL, American College of Surgeons, 1996
29. Automatch. 4.0. Silver Springs, MD, Matchware Technologies, 1996
30. Zhang JX, Iwashyna TJ, Christakis NA: The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. Med Care 37:1128-1139, 1999
31. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
32. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
33. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY, Wiley, 1987
34. Schafer JL: Multiple imputation: A primer. Stat Methods Med Res 8:3-15, 1999
35. Rasbash J, Browne W, Goldstein H, et al: A User's Guide to MLwiN, Version 2.1. London, United Kingdom, Institute of Education, University of London, 2000
36. Guadagnoli E, Weitberg A, Mor V, et al: The influence of patient age on the diagnosis and treatment of lung and colorectal cancer. Arch Intern Med 150:1485-1490, 1990
37. Coburn MC, Pricolo VE, Soderberg CH: Factors affecting prognosis and management of carcinoma of the colon and rectum in patients more than eighty years of age. J Am Coll Surg 179:65-69, 1994
38. Schroen AT, Cress RD: Use of surgical procedures and adjuvant therapy in rectal cancer treatment: A population-based study. Ann Surg 234:641-651, 2001
39. Potosky AL, Harlan LC, Kaplan RS, et al: Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192-2002, 2002
40. Yancik R, Wesley MN, Ries LAG, et al: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. Cancer 82:2123-2134, 1998
41. Popescu RA, Norman A, Ross PJ, et al: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17:2412-2418, 1999
42. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
43. Arveux I, Boutron MC, El Mrini T, et al: Colon cancer in the elderly: Evidence for major improvements in health care and survival. Br J Cancer 76:963-967, 1997
44. Kohne C-H, Grothey A, Bokemeyer C, et al: Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 12:435-442, 2001
45. Muss HB: Older age: Not a barrier to cancer treatment. N Engl J Med 345:1127-1128, 2001
46. Mandelblatt JS, Yabroff KR, Kerner JF: Equitable access to cancer services: A review of barriers to quality care. Cancer 86:2378-2390, 1999
47. Greenberg ER, Chute CG, Stukel T, et al: Social and economic factors in the choice of lung cancer treatment: A population-based study in two rural states. N Engl J Med 318:612-617, 1988
48. Roetzheim RG, Pal N, Gonzalez EC, et al: Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 90:1746-1754, 2000
49. Schrag D, Cramer LD, Bach PB, et al: Influence of hospital procedure volume on outcomes following surgery for colon cancer. J Am Med Assoc 284:3028-3035, 2000
50. Stockton D, Davies T: Multiple cancer site comparison of adjusted survival by hospital of treatment: An East Anglian study. Br J Cancer 82:208-212, 2000
51. Maurel J, Launoy G, Grosclaude P, et al: Contribution of cancer registries to the evaluation of cancer treatment: On the example of rectal cancer. Ann Chir 50:865-874, 1996
52. Wingo PA, Luke F, O'Brien K, et al: Population-based patterns of care studies: Collaboration among state cancer registries, the American College of Surgeons, and the American Cancer Society. J Reg Mgmt 28:5-16, 2001
53. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-Tumor Registry Database. Med Care 31:732-748, 1993
54. Du X, Freeman JL, Goodwin JS: Information on radiation treatment in patients with breast cancer: The advantages of the linked Medicare and SEER data. J Clin Epidemiol 52:463-470, 1999
55. Cooper GS, Yuan Z, Stange KC, et al: Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care 38:411-421, 2000